Related Experiment Videos
Progressive pulmonary fibrosis complicating cyclophosphamide therapy
Acta Medica Scandinavica
|January 1, 1987
Summary
Cyclophosphamide treatment for Wegener's granulomatosis can lead to irreversible lung fibrosis. This serious side effect, characterized by apical fibrosis and restrictive ventilatory defect, may persist even after therapy cessation.
Area of Science:
- Pulmonology
- Rheumatology
- Toxicology
Background:
- Wegener's granulomatosis, now known as Granulomatosis with Polyangiitis (GPA), is a systemic vasculitis.
- Cyclophosphamide is a potent immunosuppressant used in treating severe autoimmune diseases like GPA.
- Extra-pulmonary manifestations require aggressive treatment regimens.
Observation:
- A 26-year-old female patient with extra-pulmonary GPA received cyclophosphamide for 3.25 years (91g cumulative dose).
- Radiological evidence of apical lung fibrosis emerged six months prior to therapy termination.
- These fibrotic changes progressed despite discontinuing cyclophosphamide treatment.
Findings:
- The patient developed severe restrictive ventilatory defect.
- The observed lung fibrosis was a progressive and irreversible complication.
- This suggests a potential long-term toxicity of cyclophosphamide therapy on lung tissue.
Implications:
- Highlights the critical need for vigilant pulmonary monitoring in patients on long-term cyclophosphamide.
- Suggests that cyclophosphamide-induced lung fibrosis may not be reversible upon drug cessation.
- Underscores the importance of risk-benefit assessment for long-term immunosuppressive therapies.